Dimension Therapeutics Announces Initiation of Phase 1/2 Study For Hemophilia B Treatment

Note: The below is an edited press release from Dimension Therapeutics, Inc. The original release can be read here. Dimension Therapeutics, Inc. announced on January 7 the initiation of a phase 1/2 study of DTX101, the company’s lead therapeutic candidate, for the treatment of patients with hemophilia B. DTX101 is designed to deliver stable expression […]

uniQure Announces Preliminary Results from Hemophilia B Gene Therapy Trial

Note: the following is the  edited form of a  press releaseoriginally published by uniQure. The full release can be read here.  On Thursday, January 7, 2016, uniQure N.V. announced preliminary topline results from the low-dose cohort of an ongoing Phase I/II clinical trial being conducted in adult hemophilia B patients treated with uniQure’s novel AAV5/FIX […]

en_USEnglish